Trump Launches TrumpRx.gov Promising Sharp Prescription Drug Price Cuts [WATCH]

President Donald J. Trump announced the launch of TrumpRx.gov this week, a new federal platform aimed at lowering prescription drug prices for American patients by providing access to discounts tied to prices paid in other developed nations, as reported by Joe Hoft.

According to information released by the Trump team, TrumpRx.gov is designed to allow patients to access large discounts on many of the most popular and highest-priced medicines in the United States.

The pricing model follows the “most-favored-nation” approach, aligning U.S. drug prices with the lowest amounts paid by comparable countries.

President Trump is fighting to get Americans the LOWEST prescription drug prices in the WORLD!

“Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices.” pic.twitter.com/5OFZ3kUQZk

— The White House (@WhiteHouse) August 1, 2025

Warning: Account balances and purchasing power no longer tell the same story. Know in 2 minutes if your retirement is working for you.

The initial launch includes medications from the first five pharmaceutical manufacturers that reached most-favored-nation pricing agreements with the Trump Administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.

This Could Be the Most Important Video Gun Owners Watch All Year

Additional drugs from other companies that have signed similar agreements are expected to be added to the platform in the coming months.

Through TrumpRx.gov, patients with valid prescriptions can access savings through downloadable or printable coupons, or through manufacturer-specific channels that are integrated directly into the website.

The administration says the goal is to provide a streamlined experience that allows patients to see savings clearly before purchasing their medications.

As of the launch, TrumpRx.gov offers reduced pricing on 40 of the most popular and expensive branded drugs in the country.

Among the price changes announced are reductions for medications used to treat diabetes, heart disease, obesity, and other conditions.

The monthly prices of Ozempic and injectable Wegovy will fall from $1,028 and $1,349, respectively, to an average price of $350 and as low as $199, depending on dosage strength.

The monthly price of the Wegovy pill will drop from $1,349 to as low as $149, depending on dosage strength. Zepbound will fall from $1,088 to an average of $346 and as low as $299, depending on dosage strength.

The administration also highlighted significant savings for fertility medications, which are often paid for out of pocket. Patients undergoing fertility treatment are expected to save more than $2,000 per cycle on average.

Gonal-F will be reduced to as low as $168 per pen, depending on dosage strength. Cetrotide will drop from $316 to $22.50, and Ovidrel will fall from $251 to $84.

Additional discounts include Bevespi Aerosphere, reduced from $458 to $51; Airsupra, reduced from $504 to $201; Eucrisa, reduced from $792 to $158; Insulin Lispro, available for as low as $25 per month; and Duavee, reduced from $202 to $30.

The Trump Administration tied the launch of TrumpRx.gov to a series of policy actions taken over the past year.

This week, President Trump took significant action to strengthen healthcare for American citizens and deliver on his promise to cut prescription drug prices.

Democrats delivered a government shutdown over free healthcare for illegal aliens. pic.twitter.com/innjQbaHFG

— The White House (@WhiteHouse) October 3, 2025

On May 12, 2025, President Trump signed an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.”

On July 31, 2025, he sent letters to major pharmaceutical manufacturers outlining steps to bring U.S. prices in line with those paid abroad.

Since September 30, 2025, the administration has announced 16 pricing deals with drugmakers.

On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom that increased the net price of new prescription drugs by 25% in the UK.

On January 15, 2026, President Trump called on Congress to enact The Great Healthcare Plan to codify savings from the pricing initiative and expand transparency across the healthcare system.

The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of LifeZette. Contact us for guidelines on submitting your own commentary.